EHAB Quote, Financials, Valuation and Earnings

CVS Health Corp. has a net margin of -14.16% compared to Enhabit, Inc.'s net margin of 2.77%. Enhabit, Inc.'s return on equity of -0.45% beat CVS Health Corp.'s return on equity of 2.28%.

Enhabit, Inc. has a consensus price target of $13.44, signalling downside risk potential of -1.22%. On the other hand CVS Health Corp. has an analysts' consensus of $96.42 which suggests that it could grow by 33.02%. Given that CVS Health Corp. has higher upside potential than Enhabit, Inc., analysts believe CVS Health Corp. is more attractive than Enhabit, Inc..

Enhabit, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CVS Health Corp. has a beta of 0.511, suggesting its less volatile than the S&P 500 by 48.916%.

Enhabit, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CVS Health Corp. offers a yield of 3.64% to investors and pays a quarterly dividend of $0.67 per share. Enhabit, Inc. pays -- of its earnings as a dividend. CVS Health Corp. pays out 191.23% of its earnings as a dividend.

Enhabit, Inc. quarterly revenues are $270.4M, which are smaller than CVS Health Corp. quarterly revenues of $105.7B. Enhabit, Inc.'s net income of -$38.3M is lower than CVS Health Corp.'s net income of $2.9B. Notably, Enhabit, Inc.'s price-to-earnings ratio is 20.35x while CVS Health Corp.'s PE ratio is 52.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enhabit, Inc. is 0.67x versus 0.23x for CVS Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.

First Physicians Capital Group, Inc. has a net margin of -14.16% compared to Enhabit, Inc.'s net margin of --. Enhabit, Inc.'s return on equity of -0.45% beat First Physicians Capital Group, Inc.'s return on equity of --.

Enhabit, Inc. has a consensus price target of $13.44, signalling downside risk potential of -1.22%. On the other hand First Physicians Capital Group, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Enhabit, Inc. has higher upside potential than First Physicians Capital Group, Inc., analysts believe Enhabit, Inc. is more attractive than First Physicians Capital Group, Inc..

Enhabit, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison First Physicians Capital Group, Inc. has a beta of 0.566, suggesting its less volatile than the S&P 500 by 43.399%.

Enhabit, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. First Physicians Capital Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enhabit, Inc. pays -- of its earnings as a dividend. First Physicians Capital Group, Inc. pays out -- of its earnings as a dividend.

Enhabit, Inc. quarterly revenues are $270.4M, which are larger than First Physicians Capital Group, Inc. quarterly revenues of --. Enhabit, Inc.'s net income of -$38.3M is higher than First Physicians Capital Group, Inc.'s net income of --. Notably, Enhabit, Inc.'s price-to-earnings ratio is 20.35x while First Physicians Capital Group, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enhabit, Inc. is 0.67x versus 1.42x for First Physicians Capital Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

The Joint Corp. (United States) has a net margin of -14.16% compared to Enhabit, Inc.'s net margin of 6.18%. Enhabit, Inc.'s return on equity of -0.45% beat The Joint Corp. (United States)'s return on equity of -1.32%.

Enhabit, Inc. has a consensus price target of $13.44, signalling downside risk potential of -1.22%. On the other hand The Joint Corp. (United States) has an analysts' consensus of $10.00 which suggests that it could grow by 16.55%. Given that The Joint Corp. (United States) has higher upside potential than Enhabit, Inc., analysts believe The Joint Corp. (United States) is more attractive than Enhabit, Inc..

Enhabit, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison The Joint Corp. (United States) has a beta of 1.224, suggesting its more volatile than the S&P 500 by 22.361%.

Enhabit, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Joint Corp. (United States) offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enhabit, Inc. pays -- of its earnings as a dividend. The Joint Corp. (United States) pays out -- of its earnings as a dividend.

Enhabit, Inc. quarterly revenues are $270.4M, which are larger than The Joint Corp. (United States) quarterly revenues of $15.2M. Enhabit, Inc.'s net income of -$38.3M is lower than The Joint Corp. (United States)'s net income of $937.1K. Notably, Enhabit, Inc.'s price-to-earnings ratio is 20.35x while The Joint Corp. (United States)'s PE ratio is 45.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enhabit, Inc. is 0.67x versus 2.30x for The Joint Corp. (United States). Usually stocks with elevated PS ratios are considered overvalued.

UNIVEC has a net margin of -14.16% compared to Enhabit, Inc.'s net margin of --. Enhabit, Inc.'s return on equity of -0.45% beat UNIVEC's return on equity of --.

Enhabit, Inc. has a consensus price target of $13.44, signalling downside risk potential of -1.22%. On the other hand UNIVEC has an analysts' consensus of -- which suggests that it could fall by --. Given that Enhabit, Inc. has higher upside potential than UNIVEC, analysts believe Enhabit, Inc. is more attractive than UNIVEC.

Enhabit, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison UNIVEC has a beta of -0.101, suggesting its less volatile than the S&P 500 by 110.112%.

Enhabit, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UNIVEC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enhabit, Inc. pays -- of its earnings as a dividend. UNIVEC pays out -- of its earnings as a dividend.

Enhabit, Inc. quarterly revenues are $270.4M, which are larger than UNIVEC quarterly revenues of --. Enhabit, Inc.'s net income of -$38.3M is higher than UNIVEC's net income of --. Notably, Enhabit, Inc.'s price-to-earnings ratio is 20.35x while UNIVEC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enhabit, Inc. is 0.67x versus -- for UNIVEC. Usually stocks with elevated PS ratios are considered overvalued.